Baseline CD4/CD8 t-cell ratio predicts prompt immune restoration upon cART initiation

Current HIV Research

Volumn 14, Issue 6, 2016, Pages 491-496

  Bellissimo, Francesco ^a   Pinzone, Marilia Rita ^a   Celesia, Benedetto Maurizio ^a   Cacopardo, Bruno ^a   Nunnari, Giuseppe ^b,c  

^a GARIBALDI HOSPITAL   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

CD4; CD8; HIV; Inflammation; T cell ratio

Indexed keywords

ATAZANAVIR; EFAVIRENZ; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BLOOD TRANSFUSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; VIRUS LOAD; CD4 CD8 RATIO; HIV INFECTIONS; IMMUNOLOGY; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84995901360     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X14666160414111554     Document Type: Article

References (41)

1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338(13): 853-60
2. Scarpino M, Pinzone MR, Di Rosa M, et al. Kidney disease in HIV-infected patients. Eur Rev Med Pharmacol Sci 2013; 17(19): 2660-7
3. Castronuovo D, Cacopardo B, Pinzone MR, et al. Bone disease in the setting of HIV infection: update and review of the literature. Eur Rev Med Pharmacol Sci 2013; 17(18): 2413-9
4. La Ferla L, Pinzone MR, Nunnari G, et al. Kaposi' s sarcoma in HIV-positive patients: the state of art in the HAART-era. Eur Rev Med Pharmacol Sci 2013; 17(17): 2354-65
5. Celesia BM, Castronuovo D, Pinzone MR, et al. Late presentation of HIV infection: predictors of delayed diagnosis and survival in Eastern Sicily. Eur Rev Med Pharmacol Sci 2013; 17(16): 2218-24
6. Pinzone MR, Di Rosa M, Malaguarnera M, et al. Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci 2013; 17(9): 1218-32
7. Pinzone MR, Fiorica F, Di Rosa M, et al. Non-AIDS-defining cancers among HIV-infected people. Eur Rev Med Pharmacol Sci 2012; 16(10): 1377-88
8. Nunnari G, Berretta M, Pinzone MR, et al. Hepatocellular carcinoma in HIV positive patients. Eur Rev Med Pharmacol Sci 2012; 16(9): 1257-70
9. Pinzone MR, Di Rosa M, Cacopardo B, Nunnari G. HIV RNA suppression and immune restoration: can we do better? Clin Dev Immunol 2012; 2012: 515962
10. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10(5): e1004078
11. Fahey JL, Giorgi J, Martinez-Maza O, et al. Immune pathogenesis of AIDS and related syndromes. Ann Inst Pasteur Immunol 1987; 138(2): 245-52
12. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) 1988; 296(6624): 745-50
13. Bouscarat F, Levacher M, Landman R, et al. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 1998; 12(11): 1267-73
14. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989; 2(2): 114-24
15. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322(3): 166-72
16. Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009; 113(23): 5737-42
17. Syrjala H, Surcel HM, Ilonen J. Low CD4/CD8 T lymphocyte ratio in acute myocardial infarction. Clin Exp Immunol 1991; 83(2): 326-8
18. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170(14): 1228-38
19. Mussini C, Lorenzini P, Cozzi-Lepri A, et al, for the Icona Foundation Study Group. CD4/CD8 ratio normalisation and non-AIDSrelated events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV 2015; 2(3): e98-e106
20. Serrano-Villar S, Pérez-Elías MJ, Dronda F, et al. Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PLoS One 2014; 9(1): e85798
21. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5(10): e203
22. Plana M, Garcia F, Gallart T, et al. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000; 14(13): 1921-33
23. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62: 141-55
24. Serrano-Villar S, Gutierrez C, Vallejo A, et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect 2013; 66(1): 57-66
25. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2016; 42(3): 418-27
26. Zaman MM, Recco RA, Raguthu L, Likki S, Reddy S. Characteristics of HIV-1-infected patients with CD4:CD8 lymphocyte ratio normalization on antiretroviral therapy. AIDS Patient Care STDS 2000; 14(12): 647-9
27. Torti C, Prosperi M, Motta D, et al. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ Tcell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Clin Microbiol Infect 2012; 18(5): 449-58
28. Leung V, Gillis J, Raboud J, et al, the CANOC Collaboration. Predictors of CD4:CD8 Ratio Normalization and Its Effect on Health Outcomes in the Era of Combination Antiretroviral Therapy. PLoS One 2013; 8(10): e77665
29. Kulkarni H, Okulicz JF, Grandits G, et al. Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2011; 57(5): 387-95
30. Margolick JB, Gange SJ, Detels R, et al. Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J Acquir Immune Defic Syndr 2006; 42(5): 620-6
31. Mendez-Lagares G, Garcia-Perganeda A, del Mar del Pozo-Balado M, et al. Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. J Antimicrob Chemother 2012; 67(5): 1228-37
32. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202(5): 673-85
33. Naeger DM, Martin JN, Sinclair E, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010; 5(1): e8886
34. Liu Z, Cumberland WG, Hultin LE, et al. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(4): 332-40
35. Bofill M, Mocroft A, Lipman M, et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 1996; 10(8): 827-34
36. Echaniz P, Arrizabalaga J, Iribarren JA, Cuadrado E. CD8+CD38+ and CD8+DR+ peripheral blood lymphoid subsets of HIV-infected intravenous drug abusers correlate with CD4+ cell counts and proliferation to mitogens. Cell Immunol 1993; 150(1): 72-80
37. Giorgi JV, Liu Z, Hultin LE, et al. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993; 6(8): 904-12
38. Moore DM, Hogg RS, Chan K, et al. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 2006; 20(3): 371-7
39. Tinago W, Coghlan E, Macken A, et al; Mater Immunology Study Group. Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+ T-cell ratio: effect of naïve and memory T-cell subsets. PLoS One 2014; 9(5): e97011
40. Serrano-Villar S, Moreno S, Fuentes-Ferrer M, et al. The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Med 2014; 15(1): 40-9
41. Sainz T, Serrano-Villar S, Díaz L, et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS. 2013; 27(9): 1513-6.